Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Giving celecoxib before
surgery may reduce the amount of normal tissue that needs to be removed. Collecting and
storing samples of tumor tissue, blood, and urine from patients with head and neck cancer to
study in the laboratory may help doctors learn more about the cancer and predict how well
patients will respond to treatment with celecoxib.
PURPOSE: This phase I/II trial is studying changes in tumor cells and how well celecoxib
works in treating patients with head and neck cancer that can be removed by surgery.